Loading…

Establishment of a novel cell cycle-related prognostic signature predicting prognosis in patients with endometrial cancer

Endometrial cancer (EnCa) ranks fourth in menace within women's malignant tumors. Large numbers of studies have proven that functional genes can change the process of tumors by regulating the cell cycle, thereby achieving the goal of targeted therapy. The transcriptional data of EnCa samples ob...

Full description

Saved in:
Bibliographic Details
Published in:Cancer cell international 2020-07, Vol.20 (1), p.329-329, Article 329
Main Authors: Liu, Jinhui, Mei, Jie, Li, Siyue, Wu, Zhipeng, Zhang, Yan
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c597t-76a72bf2744ab8dadd96d27e82c48d3021a8d0a7819e219a63b2a5e169cb918d3
cites cdi_FETCH-LOGICAL-c597t-76a72bf2744ab8dadd96d27e82c48d3021a8d0a7819e219a63b2a5e169cb918d3
container_end_page 329
container_issue 1
container_start_page 329
container_title Cancer cell international
container_volume 20
creator Liu, Jinhui
Mei, Jie
Li, Siyue
Wu, Zhipeng
Zhang, Yan
description Endometrial cancer (EnCa) ranks fourth in menace within women's malignant tumors. Large numbers of studies have proven that functional genes can change the process of tumors by regulating the cell cycle, thereby achieving the goal of targeted therapy. The transcriptional data of EnCa samples obtained from the TCGA database was analyzed. A battery of bioinformatics strategies, which included GSEA, Cox and LASSO regression analysis, establishment of a prognostic signature and a nomogram for overall survival (OS) assessment. The GEPIA and CPTAC analysis were applied to validate the dysregulation of hub genes. For mutation analysis, the "maftools" package was used. GSEA identified that cell cycle was the most associated pathway to EnCa. Five cell cycle-related genes including HMGB3, EZH2, NOTCH2, UCK2 and ODF2 were identified as prognosis-related genes to build a prognostic signature. Based on this model, the EnCa patients could be divided into low- and high-risk groups, and patients with high-risk score exhibited poorer OS. Time-dependent ROC and Cox regression analyses revealed that the 5-gene signature could predict EnCa prognosis exactly and independently. GEPIA and CPTAC validation exhibited that these genes were notably dysregulated between EnCa and normal tissues. Lower mutation rates of PTEN, TTN, ARID1A, and etc. were found in samples with high-risk score compared with that with low-risk score. GSEA analysis suggested that the samples of the low- and high-risk groups were concentrated on various pathways, which accounted for the different oncogenic mechanisms in patients in two groups. The current research construct a 5-gene signature to evaluate prognosis of EnCa patients, which may innovative clinical application of prognostic assessment.
doi_str_mv 10.1186/s12935-020-01428-z
format article
fullrecord <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_54a098ad8c004d2aa421fb646256cf15</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_54a098ad8c004d2aa421fb646256cf15</doaj_id><sourcerecordid>2435246615</sourcerecordid><originalsourceid>FETCH-LOGICAL-c597t-76a72bf2744ab8dadd96d27e82c48d3021a8d0a7819e219a63b2a5e169cb918d3</originalsourceid><addsrcrecordid>eNpdksFu1DAQhiMEoqXwAhxQJC5cAvbEsZ0LEqoKVKrEBc7WxHayXiX2Yjuttk-Pu9tWLRePNfPPp5nRX1XvKflMqeRfEoW-7RoCpCGUgWxuX1SnlImuAcnFyyf_k-pNSltCqJCcvK5OWuB934E8rfYXKeMwu7RZrM91GGusfbi2c63tXJ69nm0T7YzZmnoXw-RDyk7XyU0e8xptSVrjdHZ-eqi7VDtf7zC7gkz1jcub2noTFpujwwJFr218W70acU723X08q_58v_h9_rO5-vXj8vzbVaO7XuRGcBQwjCAYw0EaNKbnBoSVoJk0LQGK0hAUkvYWaI-8HQA7S3mvh54WxVl1eeSagFu1i27BuFcBnTokQpwUxrLSbFXHkPQSjdSEMAOIDOg4cMah43qkXWF9PbJ267BYo8t-Eedn0OcV7zZqCtdKtAKkbAvg0z0ghr-rTVktLt1dGr0Na1LAgHetbAUt0o__Sbdhjb6cqqjaDhjnh4ngqNIxpBTt-DgMJerOJeroElVcog4uUbel6cPTNR5bHmzR_gM3T7tc</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2435246615</pqid></control><display><type>article</type><title>Establishment of a novel cell cycle-related prognostic signature predicting prognosis in patients with endometrial cancer</title><source>Open Access: PubMed Central</source><source>Publicly Available Content Database</source><creator>Liu, Jinhui ; Mei, Jie ; Li, Siyue ; Wu, Zhipeng ; Zhang, Yan</creator><creatorcontrib>Liu, Jinhui ; Mei, Jie ; Li, Siyue ; Wu, Zhipeng ; Zhang, Yan</creatorcontrib><description>Endometrial cancer (EnCa) ranks fourth in menace within women's malignant tumors. Large numbers of studies have proven that functional genes can change the process of tumors by regulating the cell cycle, thereby achieving the goal of targeted therapy. The transcriptional data of EnCa samples obtained from the TCGA database was analyzed. A battery of bioinformatics strategies, which included GSEA, Cox and LASSO regression analysis, establishment of a prognostic signature and a nomogram for overall survival (OS) assessment. The GEPIA and CPTAC analysis were applied to validate the dysregulation of hub genes. For mutation analysis, the "maftools" package was used. GSEA identified that cell cycle was the most associated pathway to EnCa. Five cell cycle-related genes including HMGB3, EZH2, NOTCH2, UCK2 and ODF2 were identified as prognosis-related genes to build a prognostic signature. Based on this model, the EnCa patients could be divided into low- and high-risk groups, and patients with high-risk score exhibited poorer OS. Time-dependent ROC and Cox regression analyses revealed that the 5-gene signature could predict EnCa prognosis exactly and independently. GEPIA and CPTAC validation exhibited that these genes were notably dysregulated between EnCa and normal tissues. Lower mutation rates of PTEN, TTN, ARID1A, and etc. were found in samples with high-risk score compared with that with low-risk score. GSEA analysis suggested that the samples of the low- and high-risk groups were concentrated on various pathways, which accounted for the different oncogenic mechanisms in patients in two groups. The current research construct a 5-gene signature to evaluate prognosis of EnCa patients, which may innovative clinical application of prognostic assessment.</description><identifier>ISSN: 1475-2867</identifier><identifier>EISSN: 1475-2867</identifier><identifier>DOI: 10.1186/s12935-020-01428-z</identifier><identifier>PMID: 32699528</identifier><language>eng</language><publisher>England: BioMed Central</publisher><subject>Bioinformatics ; Cell cycle ; Childrens health ; Endometrial cancer ; Endometrium ; Genes ; GSEA ; Maternal &amp; child health ; Medical prognosis ; Mutation ; Mutation rates ; Nomograms ; Patients ; Primary Research ; Prognosis ; Prognostic model ; PTEN protein ; Regression analysis ; Risk groups ; Software ; Survival analysis ; TCGA ; Transcription ; Tumors</subject><ispartof>Cancer cell international, 2020-07, Vol.20 (1), p.329-329, Article 329</ispartof><rights>The Author(s) 2020.</rights><rights>2020. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>The Author(s) 2020</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c597t-76a72bf2744ab8dadd96d27e82c48d3021a8d0a7819e219a63b2a5e169cb918d3</citedby><cites>FETCH-LOGICAL-c597t-76a72bf2744ab8dadd96d27e82c48d3021a8d0a7819e219a63b2a5e169cb918d3</cites><orcidid>0000-0002-7983-8396</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7372883/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2435246615?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,25753,27924,27925,37012,37013,44590,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32699528$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Liu, Jinhui</creatorcontrib><creatorcontrib>Mei, Jie</creatorcontrib><creatorcontrib>Li, Siyue</creatorcontrib><creatorcontrib>Wu, Zhipeng</creatorcontrib><creatorcontrib>Zhang, Yan</creatorcontrib><title>Establishment of a novel cell cycle-related prognostic signature predicting prognosis in patients with endometrial cancer</title><title>Cancer cell international</title><addtitle>Cancer Cell Int</addtitle><description>Endometrial cancer (EnCa) ranks fourth in menace within women's malignant tumors. Large numbers of studies have proven that functional genes can change the process of tumors by regulating the cell cycle, thereby achieving the goal of targeted therapy. The transcriptional data of EnCa samples obtained from the TCGA database was analyzed. A battery of bioinformatics strategies, which included GSEA, Cox and LASSO regression analysis, establishment of a prognostic signature and a nomogram for overall survival (OS) assessment. The GEPIA and CPTAC analysis were applied to validate the dysregulation of hub genes. For mutation analysis, the "maftools" package was used. GSEA identified that cell cycle was the most associated pathway to EnCa. Five cell cycle-related genes including HMGB3, EZH2, NOTCH2, UCK2 and ODF2 were identified as prognosis-related genes to build a prognostic signature. Based on this model, the EnCa patients could be divided into low- and high-risk groups, and patients with high-risk score exhibited poorer OS. Time-dependent ROC and Cox regression analyses revealed that the 5-gene signature could predict EnCa prognosis exactly and independently. GEPIA and CPTAC validation exhibited that these genes were notably dysregulated between EnCa and normal tissues. Lower mutation rates of PTEN, TTN, ARID1A, and etc. were found in samples with high-risk score compared with that with low-risk score. GSEA analysis suggested that the samples of the low- and high-risk groups were concentrated on various pathways, which accounted for the different oncogenic mechanisms in patients in two groups. The current research construct a 5-gene signature to evaluate prognosis of EnCa patients, which may innovative clinical application of prognostic assessment.</description><subject>Bioinformatics</subject><subject>Cell cycle</subject><subject>Childrens health</subject><subject>Endometrial cancer</subject><subject>Endometrium</subject><subject>Genes</subject><subject>GSEA</subject><subject>Maternal &amp; child health</subject><subject>Medical prognosis</subject><subject>Mutation</subject><subject>Mutation rates</subject><subject>Nomograms</subject><subject>Patients</subject><subject>Primary Research</subject><subject>Prognosis</subject><subject>Prognostic model</subject><subject>PTEN protein</subject><subject>Regression analysis</subject><subject>Risk groups</subject><subject>Software</subject><subject>Survival analysis</subject><subject>TCGA</subject><subject>Transcription</subject><subject>Tumors</subject><issn>1475-2867</issn><issn>1475-2867</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNpdksFu1DAQhiMEoqXwAhxQJC5cAvbEsZ0LEqoKVKrEBc7WxHayXiX2Yjuttk-Pu9tWLRePNfPPp5nRX1XvKflMqeRfEoW-7RoCpCGUgWxuX1SnlImuAcnFyyf_k-pNSltCqJCcvK5OWuB934E8rfYXKeMwu7RZrM91GGusfbi2c63tXJ69nm0T7YzZmnoXw-RDyk7XyU0e8xptSVrjdHZ-eqi7VDtf7zC7gkz1jcub2noTFpujwwJFr218W70acU723X08q_58v_h9_rO5-vXj8vzbVaO7XuRGcBQwjCAYw0EaNKbnBoSVoJk0LQGK0hAUkvYWaI-8HQA7S3mvh54WxVl1eeSagFu1i27BuFcBnTokQpwUxrLSbFXHkPQSjdSEMAOIDOg4cMah43qkXWF9PbJ267BYo8t-Eedn0OcV7zZqCtdKtAKkbAvg0z0ghr-rTVktLt1dGr0Na1LAgHetbAUt0o__Sbdhjb6cqqjaDhjnh4ngqNIxpBTt-DgMJerOJeroElVcog4uUbel6cPTNR5bHmzR_gM3T7tc</recordid><startdate>20200720</startdate><enddate>20200720</enddate><creator>Liu, Jinhui</creator><creator>Mei, Jie</creator><creator>Li, Siyue</creator><creator>Wu, Zhipeng</creator><creator>Zhang, Yan</creator><general>BioMed Central</general><general>BMC</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TM</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>M0S</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0002-7983-8396</orcidid></search><sort><creationdate>20200720</creationdate><title>Establishment of a novel cell cycle-related prognostic signature predicting prognosis in patients with endometrial cancer</title><author>Liu, Jinhui ; Mei, Jie ; Li, Siyue ; Wu, Zhipeng ; Zhang, Yan</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c597t-76a72bf2744ab8dadd96d27e82c48d3021a8d0a7819e219a63b2a5e169cb918d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Bioinformatics</topic><topic>Cell cycle</topic><topic>Childrens health</topic><topic>Endometrial cancer</topic><topic>Endometrium</topic><topic>Genes</topic><topic>GSEA</topic><topic>Maternal &amp; child health</topic><topic>Medical prognosis</topic><topic>Mutation</topic><topic>Mutation rates</topic><topic>Nomograms</topic><topic>Patients</topic><topic>Primary Research</topic><topic>Prognosis</topic><topic>Prognostic model</topic><topic>PTEN protein</topic><topic>Regression analysis</topic><topic>Risk groups</topic><topic>Software</topic><topic>Survival analysis</topic><topic>TCGA</topic><topic>Transcription</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Liu, Jinhui</creatorcontrib><creatorcontrib>Mei, Jie</creatorcontrib><creatorcontrib>Li, Siyue</creatorcontrib><creatorcontrib>Wu, Zhipeng</creatorcontrib><creatorcontrib>Zhang, Yan</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nucleic Acids Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Health &amp; Medical Collection (Proquest)</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>Directory of Open Access Journals</collection><jtitle>Cancer cell international</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Liu, Jinhui</au><au>Mei, Jie</au><au>Li, Siyue</au><au>Wu, Zhipeng</au><au>Zhang, Yan</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Establishment of a novel cell cycle-related prognostic signature predicting prognosis in patients with endometrial cancer</atitle><jtitle>Cancer cell international</jtitle><addtitle>Cancer Cell Int</addtitle><date>2020-07-20</date><risdate>2020</risdate><volume>20</volume><issue>1</issue><spage>329</spage><epage>329</epage><pages>329-329</pages><artnum>329</artnum><issn>1475-2867</issn><eissn>1475-2867</eissn><abstract>Endometrial cancer (EnCa) ranks fourth in menace within women's malignant tumors. Large numbers of studies have proven that functional genes can change the process of tumors by regulating the cell cycle, thereby achieving the goal of targeted therapy. The transcriptional data of EnCa samples obtained from the TCGA database was analyzed. A battery of bioinformatics strategies, which included GSEA, Cox and LASSO regression analysis, establishment of a prognostic signature and a nomogram for overall survival (OS) assessment. The GEPIA and CPTAC analysis were applied to validate the dysregulation of hub genes. For mutation analysis, the "maftools" package was used. GSEA identified that cell cycle was the most associated pathway to EnCa. Five cell cycle-related genes including HMGB3, EZH2, NOTCH2, UCK2 and ODF2 were identified as prognosis-related genes to build a prognostic signature. Based on this model, the EnCa patients could be divided into low- and high-risk groups, and patients with high-risk score exhibited poorer OS. Time-dependent ROC and Cox regression analyses revealed that the 5-gene signature could predict EnCa prognosis exactly and independently. GEPIA and CPTAC validation exhibited that these genes were notably dysregulated between EnCa and normal tissues. Lower mutation rates of PTEN, TTN, ARID1A, and etc. were found in samples with high-risk score compared with that with low-risk score. GSEA analysis suggested that the samples of the low- and high-risk groups were concentrated on various pathways, which accounted for the different oncogenic mechanisms in patients in two groups. The current research construct a 5-gene signature to evaluate prognosis of EnCa patients, which may innovative clinical application of prognostic assessment.</abstract><cop>England</cop><pub>BioMed Central</pub><pmid>32699528</pmid><doi>10.1186/s12935-020-01428-z</doi><tpages>1</tpages><orcidid>https://orcid.org/0000-0002-7983-8396</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1475-2867
ispartof Cancer cell international, 2020-07, Vol.20 (1), p.329-329, Article 329
issn 1475-2867
1475-2867
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_54a098ad8c004d2aa421fb646256cf15
source Open Access: PubMed Central; Publicly Available Content Database
subjects Bioinformatics
Cell cycle
Childrens health
Endometrial cancer
Endometrium
Genes
GSEA
Maternal & child health
Medical prognosis
Mutation
Mutation rates
Nomograms
Patients
Primary Research
Prognosis
Prognostic model
PTEN protein
Regression analysis
Risk groups
Software
Survival analysis
TCGA
Transcription
Tumors
title Establishment of a novel cell cycle-related prognostic signature predicting prognosis in patients with endometrial cancer
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T05%3A42%3A50IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Establishment%20of%20a%20novel%20cell%20cycle-related%20prognostic%20signature%20predicting%20prognosis%20in%20patients%20with%20endometrial%20cancer&rft.jtitle=Cancer%20cell%20international&rft.au=Liu,%20Jinhui&rft.date=2020-07-20&rft.volume=20&rft.issue=1&rft.spage=329&rft.epage=329&rft.pages=329-329&rft.artnum=329&rft.issn=1475-2867&rft.eissn=1475-2867&rft_id=info:doi/10.1186/s12935-020-01428-z&rft_dat=%3Cproquest_doaj_%3E2435246615%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c597t-76a72bf2744ab8dadd96d27e82c48d3021a8d0a7819e219a63b2a5e169cb918d3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2435246615&rft_id=info:pmid/32699528&rfr_iscdi=true